Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAMELA: Lapatinib Plus Trastuzumab in Early HER2-positive Breast Cancer
NCT01973660Phase 2Completed
- Sponsor
- SOLTI
- Start
- Oct 2013
- Primary completion
- Jun 2016
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib, trastuzumab in breast cancer, sponsored by SOLTI. Started Oct 2013; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01973660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973660.